BCN-DOTA

• UNSPSC Description:

  BCN-DOTA is a cyclooctyne-linked DOTA chelator that can be radiolabeled with zirconium-89 as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells, or tissues.

• Target Antigen:

  Radionuclide-Drug Conjugates (RDCs)

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/bcn-dota.html

• Smiles:

  O=C(NCCNC(OC[C@H]1[C@@]2([H])CCC#CCC[C@@]12[H])=O)CN3CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC3

• Molecular Weight:

  622.71

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2565792-45-0